Trial Profile
A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Panobinostat (Primary)
- Indications Burkitt's lymphoma; Extranodal NK-T-cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoid leukaemia; Lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Primary-Effusion-Lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 02 Mar 2020 Status changed from active, no longer recruiting to completed.
- 02 Mar 2020 Status changed from active, no longer recruiting to completed.
- 18 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.